Platelets and diabetes mellitus

Prostaglandins and Other Lipid Mediators

Volumn 120, Issue , 2015, Pages 28-39

  Santilli, Francesca ^a   Simeone, Paola ^a   Liani, Rossella ^a   Davì, Giovanni ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

ASA responsiveness; Diabetes mellitus; Oxidative stress; Platelet activation; Platelet turnover; Platelet derived inflammatory proteins

Indexed keywords

ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTITHROMBOCYTIC AGENT; CD36 ANTIGEN; CD40 LIGAND; CHEMOKINE; CYTOKINE; DICKKOPF 1 PROTEIN; PLATELET DERIVED INFLAMMATORY PROTEIN; PROTEIN; PURINERGIC P2Y RECEPTOR ANTAGONIST; THROMBOXANE; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR RISK; CELL ACTIVATION; CELL INTERACTION; CYTOKINE RELEASE; DIABETES MELLITUS; GLUCOSE METABOLISM; GLYCEMIC VARIABILITY; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOSIS; ANIMAL; BLOOD; CARDIOVASCULAR DISEASE; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; PHYSIOLOGY;

ANIMALS; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; OXIDATIVE STRESS; PLATELET AGGREGATION INHIBITORS; THROMBOXANES;

EID: 84941808117     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2015.05.002     Document Type: Review

References (149)

1. E.W. Gregg, Y. Li, J. Wang, and et al. Changes in diabetes-related complications in the United States, 1990-2010 N Eng J Med 370 2014 1514 1523
2. S.M. Haffner, S. Lehto, T. Ronnemaa, and et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 1998 229 234
3. B. Stratmann, and D. Tschoepe Heart in diabetes: not only a macrovascular disease Diabetes Care 34 2011 S138 S144
4. C.S. Fox, S. Coady, P.D. Sorlie, and et al. Trends in cardiovascular complications of diabetes JAMA 292 2004 2495 2499
5. I.M. Stratton, A.I. Adler, H.A. Neil, and et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 321 2000 405 412
6. J.F. Mustard, and M.A. Packham Platelets and diabetes mellitus N Engl J Med 311 1984 665 667
7. 2 in man Biochim Biophys Acta 992 1989 66 70
8. G.A. FitzGerald, A.K. Pedersen, and C. Patrono Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease Circulation 67 1983 1174 1177
9. J. Nowak, J.J. Murray, J.A. Oates, and G.A. FitzGerald Biochemical evidence of a chronic abnormality in platelet and arterial function in healthy individuals who smoke cigarettes Circulation 76 1987 6 14
10. G. Davì, I. Catalano, M. Averna, and et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus N Engl J Med 322 1990 1769 1774
11. G. Davì, M. Averna, I. Catalano, and et al. Increased thromboxane biosynthesis in type IIa hypercholesterolemia Circulation 85 1992 1792 1798
12. G. Di Minno, G. Davì, M. Margaglione, and et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuria: evidence for platelet involvement and probucol-sensitive mechanism J Clin Invest 92 1993 1400 1406
13. G. Davì, P. Gresele, F. Violi, and et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease Circulation 96 1997 69 75
14. J.M. Bridges, A.M. Dalby, J.H.D. Millar, and J.A. Weaver An effect of d-glucose on platelet stickiness Lancet 1 1965 75 77
15. 2 in non-insulin-dependent diabetes: relationship to vascular complications Eur J Clin Invest 14 1984 83 86
16. H.J. Oskarsson, and T.G. Hofmeyer Platelets from diabetic patients with diabetes mellitus have impaired ability to mediate vasodilation J Am Coll Cardiol 27 1996 1464 1470
17. 2 formation and platelet sensitivity to prostacyclin in insulin-dependent and insulin-independent diabetics Thromb Res 26 1982 359 370
18. S.M. Knebel, R.S. Sprague, and A.H. Stephenson Prostacyclin receptor expression on platelets of humans with type 2 diabetes is inversely correlated with hemoglobin A1c levels Prostaglandins Other Lipid Mediat 116-117 2015 131 135
19. A.I. Vinik, T. Erbas, T.S. Park, R. Nolan, and G.L. Pittenger Platelet dysfunction in type 2 diabetes Diabetes Care 24 2001 1476 1485
20. G. Triolo, G. Davì, E. Giardina, and et al. Circulating immune complexes and platelet thromboxane synthesis in patients with insulin-dependent (type I) diabetes mellitus Diabetes 33 1984 728 731
21. R. Hernández Vera, G. Vilahur, R. Ferrer-Lorente, E. Peña, and L. Badimon Platelets derived from the bone marrow of diabetic animals show dysregulated endoplasmic reticulum stress proteins that contribute to increased thrombosis Arterioscler Thromb Vasc Biol 32 2012 2141 2148
22. G. Davì, G. Ciabattoni, A. Consoli, and et al. In vivo formation of 8-iso-prostaglandin F2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation Circulation 99 1999 224 229
23. P. Gresele, G. Guglielmini, M. De Angelis, and et al. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus J Am Coll Cardiol 41 2003 1013 1020
24. H. Ha, and H.B. Lee Oxidative stress in diabetic nephropathy: basic and clinical information Curr Diab Rep 1 2001 282 287
25. C. Patrono, and G.A. FitzGerald Isoprostanes: potential markers of oxidant stress in atherothrombotic disease Arterioscler Thromb Vasc Biol 17 1997 2309 2315
26. J. Zhang, G. Johnston, B. Stebler, and E.T. Keller Hydrogen peroxide activates NFκB and the interleukin-6 promoter through NFκB-inducing kinase Antioxid Redox Signal 3 2001 493 504
27. R. De Cristofaro, B. Rocca, E. Vitacolonna, and et al. Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus J Thromb Haemost 1 2003 250 256
28. H.H. Refsgaard, L. Tsai, and E.R. Stadtman Modifications of proteins by polyunsaturated fatty acid peroxidation products Proc Natl Acad Sci U S A 97 2000 611 616
29. S.R. Lentz, and J.E. Sadler Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine J Clin Invest 88 1991 1906 1914
30. C.B. Glaser, J. Morser, J.H. Clarke, and et al. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation J Clin Invest 90 1992 2565 2573
31. D. Blache, E. Bourdon, P. Salloignon, and et al. Glycated albumin with loss of fatty acid binding capacity contributes to enhanced arachidonate oxygenation and platelet hyperactivity: relevance in patients with type 2 diabetes Diabetes 64 2015 960 972
32. E. Coban, F. Bostan, and M. Ozdogan The mean platelet volume in subjects with impaired fasting glucose Platelets 17 2006 67 69
33. F. Santilli, G. Formoso, P. Sbraccia, and et al. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus J Thromb Haemost 8 2010 828 837
34. B. Balkau The DECODE study. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe Diabetes Metab 26 2000 282 286
35. F. Cavalot, A. Petrelli, M. Traversa, and et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study J Clin Endocrinol Metab 91 2006 813 819
36. L. Monnier, C. Colette, and D.R. Owens Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept Diabetes Metab Res Rev 25 2009 393 402
37. P. Ferroni, S. Basili, A. Falco, and G. Davì Platelet activation in type 2 diabetes mellitus J Thromb Haemost 2 2004 1282 1291
38. F. Ciaffardini, G. Davì, P. Di Fulvio, and et al. In vivo platelet activation in impaired glucose tolerance and during progression of type 2 diabetes: a cross-sectional and longitudinal study Circulation 130 2014 A17186
39. F. Paneni, S. Costantino, and F. Cosentino Molecular mechanisms of vascular dysfunction and cardiovascular biomarkers in type 2 diabetes Cardiovasc Diagn Ther 4 2014 324 332
40. L. Monnier, E. Mas, C. Ginet, and et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes JAMA 295 2006 1681 1687
41. M. Brownlee Biochemistry and molecular cell biology of diabetic complications Nature 414 2001 813 820
42. M. Brownlee The pathophysiology of diabetic complications: a unifying mechanism Diabetes 54 2005 1615 1625
43. L. Monnier, H. Lapinski, and C. Colette Contribution of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c Diabetes Care 26 2003 881 885
44. M. Metzger, G. Leibovitz, J. Wainstein, B. Glaser, and I. Raz Reproducibility of glucose measurements using the glucose sensor Diabetes Care 25 2002 1185 1191
45. F.J. Service, G.D. Molnar, J.W. Rosevear, and et al. Mean amplitude of glycemic excursions, a measure of diabetic instability Diabetes 19 1970 644 655
46. F.J. Service, P.C. O'Brien, and R.A. Rizza Measurements of glucose control Diabetes Care 10 1987 225 237
47. S. Basili, G. Pacini, M.T. Guagnano, and et al. Insulin resistance as a determinant of platelet activation in obese women J Am Coll Cardiol 48 2006 2531 2538
48. J.P. Despres, B. La marche, P. Mauriege, and et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease N Engl J Med 334 1996 952 957
49. G.J. Blake, and P.M. Ridker Novel clinical markers of vascular wall inflammation Circ Res 89 2001 763 771
50. A. Festa, A.J. Hanley, R.P. Tracy, R. D'Agostino Jr., and S.M. Haffner Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion Circulation 108 2003 1822 1830
51. C. Falcon, G. Pfliegler, H. Deckmyn, and J. Vermylen The platelet insulin receptor: detection, partial characterization, and search for a function Biochem Biophys Res Commun 30 1988 1190 1196
52. M. Trovati, and G. Anfossi Influence of insulin and of insulin resistance on platelet and vascular smooth muscle cell function J Diabetes Complicat 16 2002 35 40
53. B.B. Kahn, and J.S. Flier Obesity and insulin resistance J Clin Invest 106 2000 473 481
54. E. Ferrannini, A. Natali, P. Bell, and et al. Insulin resistance and hypersecretion in obesity J Clin Invest 100 1997 1166 1173
55. G. Davì, M.T. Guagnano, G. Ciabattoni, and et al. Platelet activation in obese women: role of inflammation and oxidant stress JAMA 288 2002 2008 2014
56. J. Nigro, N. Osman, A.M. Dart, and P.J. Little Insulin resistance and atherosclerosis Endocr Rev 27 2006 242 259
57. M. Trovati, E.M. Mularoni, S. Burzacca, and et al. Impaired insulin-induced platelet antiaggregating effect in obesity and in obese NIDDM patients Diabetes 44 1995 1318 1322
58. J.A. Kim, M. Montagnani, K.K. Koh, and M.J. Quon Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms Circulation 113 2006 1888 1904
59. D.C. Calverley, M.R. Hacker, K.A. Loda, and et al. Increased platelet Fc receptor expression as a potential contributing cause of platelet hypersensitivity to collagen in diabetes mellitus Br J Haematol 121 2003 139 142
60. V. Henn, J.R. Slupsky, M. Grafe, and et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells Nature 391 1998 591 594
61. P. Andre, K.S. Prasad, C.V. Denis, and et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism Nat Med 8 2002 247 252
62. L. Zhou, P. Stordeur, A. de Lavareille, and et al. CD40 engagement on endothelial cells promotes tissue factor-dependent procoagulant activity Thromb Haemost 79 1998 1025 1028
63. S. Chakrabarti, S. Varghese, O. Vitseva, K. Tanriverdi, and J.E. Freedman CD40 ligand influences platelet release of reactive oxygen intermediates Arterioscler Thromb Vasc Biol 25 2005 2428 2434
64. M. Lajer, I. Tarnow, A.D. Michelson, and et al. Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function Platelets 21 2010 525 532
65. Y. Jinchuan, W. Zonggui, C. Jinming, L. Li, and K. Xiantao Upregulation of CD40-CD40 ligand system in patients with diabetes mellitus Clin Chim Acta 339 2004 85 90
66. N. Varo, P. Libby, R. Nuzzo, and et al. Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products Diab Vasc Dis Res 2 2005 81 87
67. M. Yngen, C.G. Ostenson, H. Hu, and et al. Enhanced P-selectin expression and increased soluble CD40 ligand in patients with Type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation Diabetologia 47 2004 537 540
68. G. Targher, and G. Zoppini Soluble CD40L in young type 1 diabetic individuals without clinical microvascular and macrovascular complications Diabetes Care 27 2004 1236 1237
69. D.P. Inwald, A. McDowall, M.J. Peters, R.E. Callard, and N.J. Klein CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation Circ Res 92 2003 1041 1048
70. G. Davì, A. Tuttolomondo, F. Santilli, and et al. CD40 ligand and MCP-1 as predictors of cardiovascular events in diabetic patients with stroke J Atheroscler Thromb 16 2009 707 713
71. M. Febbraio, D.P. Hajjar, and R.L. Silverstein CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism J Clin Invest 108 2001 785 791
72. R.L. Silverstein, and M. Febbraio CD36 and atherosclerosis Curr Opin Lipidol 11 2000 483 491
73. P. Libby Inflammation in atherosclerosis Nature 420 2002 868 874
74. A.C. Nicholson, M. Febbraio, J. Han, R.L. Silverstein, and D.P. Hajjar CD36 in atherosclerosis: the role of a class B macrophage scavenger receptor Ann N Y Acad Sci 902 2000 128 131
75. M.J. Sampson, I.R. Davies, S. Braschi, K. Ivory, and D.A. Hughes Increased expression of a scavenger receptor (CD36) in monocytes from subjects with type 2 diabetes Atherosclerosis 167 2003 129 134
76. T.T. Tuomisto, M.S. Riekkinen, H. Viita, A.L. Levonen, and S. Yla-Herttuala Analysis of gene and protein expression during monocyte-macrophage differentiation and cholesterol loading: cDNA and protein array study Atherosclerosis 180 2005 283 291
77. A. Nakata, Y. Nakagawa, M. Nishida, and et al. CD36, a novel receptor for oxidized low-density lipoproteins, is highly expressed on lipid-laden macrophages in human atherosclerotic aorta Arterioscler Thromb Vasc Biol 19 1999 1333 1339
78. T. Nakagawa, S. Nozaki, M. Nishida, and et al. Oxidized LDL increases and interferon-gamma decreases expression of CD36 in human monocyte-derived macrophages Arterioscler Thromb Vasc Biol 18 1998 1350 1357
79. M.M. Huang, J.B. Bolen, J.W. Barnwell, S.J. Shattil, and J.S. Brugge Membrane glycoprotein IV (CD36) is physically associated with the Fyn, Lyn, and Yes proteintyrosine kinases in human platelets Proc Natl Acad Sci U S A 88 1991 7844 7848
80. S.P. Jackson, and A.C. Calkin The clot thickens-oxidized lipids and thrombosis Nat Med 13 2007 1015 1016
81. R. Liani, B. Halvorsen, S. Sestili, and et al. Plasma levels of soluble CD36, platelet activation, inflammation and oxidative stress are increased in type 2 diabetic patients Free Radic Biol Med 52 2012 1318 1324
82. D.P. Koonen, M.K. Jensen, and A. Handberg Soluble CD36-a marker of the (pathophysiological) role of CD36 in the metabolic syndrome? Arch Physiol Biochem 117 2011 57 63
83. D. Glintborg, K. Højlund, M. Andersen, J.E. Henriksen, H. Beck-Nielsen, and A. Handberg Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment Diabetes Care 31 2008 328 334
84. A. Handberg, A. Lopez-Bermejo, J. Bassols, J. Vendrell, W. Ricart, and J.M. Fernandez-Real Circulating soluble CD36 is associated with glucose metabolism and interleukin-6 in glucose-intolerant men Diab Vasc Dis Res 6 2009 15 20
85. C. Patrono, A. Falco, and G. Davì Isoprostane formation and inhibition in atherothrombosis Curr Opin Pharmacol 5 2005 198 203
86. M.L. Liu, K. Ylitalo, R. Salonen, J.T. Salonen, and M.R. Taskinen Circulating oxidized low-density lipoprotein and its association with carotid intima-media thickness in asymptomatic members of familial combined hyperlipidemia families Arterioscler Thromb Vasc Biol 24 2004 1492 1497
87. K. Chen, M. Febbraio, W. Li, and R.L. Silverstein A specific CD36-dependent signaling pathway is required for platelet activation by oxidized low-density lipoprotein Circ Res 102 2008 1512 1519
88. Y.M. Park, M. Febbraio, and R.L. Silverstein CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contribute to macrophage trapping in the arterial intima J Clin Invest 119 2009 136 145
89. A. Goldin, J.A. Beckman, A.M. Schmidt, and M.A. Creager Advanced glycation end products: sparking the development of diabetic vascular injury Circulation 114 2006 597 605
90. A.M. Schmidt, S.D. Yan, S.F. Yan, and D.M. Stern The biology of the receptor for advanced glycation end products and its ligands Biochim Biophys Acta 1498 2000 99 111
91. A.M. Schmidt, S.D. Yan, S.F. Yan, and D.M. Stern The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses J Clin Invest 108 2001 949 955
92. R.N. Hasan, S. Phukan, and S. Harada Differential regulation of early growth response gene-1 expression by insulin and glucose in vascular endothelial cells Arterioscler Thromb Vasc Biol 23 2003 988 995
93. F. Santilli, N. Vazzana, L.G. Bucciarelli, and G. Davì Soluble forms of RAGE in human diseases: clinical and therapeutical implications Curr Med Chem 16 2009 940 952
94. G. Basta, A.M. Sironi, G. Lazzerini, and et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein J Clin Endocrinol Metab 91 2006 4628 4634
95. N. Vazzana, F. Santilli, C. Cuccurullo, and G. Davì Soluble forms of RAGE in internal medicine Intern Emerg Med 4 2009 389 401
96. E. Devangelio, F. Santilli, G. Formoso, and et al. Soluble RAGE in type 2 diabetes: association with oxidative stress Free Radic Biol Med 43 2007 511 518
97. G. Davì, and C. Patrono Platelet activation and atherothrombosis N Engl J Med 357 2007 2482 2494
98. T. Gawlowski, B. Stratmann, R. Ruetter, and et al. Advanced glycation end products strongly activate platelets Eur J Nutr 48 2009 475 481
99. E. Fuentes, A. Rojas, and I. Palomo Role of multiligand/RAGE axis in platelet activation Thromb Res 133 2014 308 314
100. Y. Yilmaz, E. Ulukaya, O.O. Gul, and et al. Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease Clin Biochem 42 2009 802 807
101. E. Ferrante, N. Vazzana, F. Santilli, and et al. Determinants of thromboxane biosynthesis in rheumatoid arthritis: role of RAGE and oxidant stress Free Radic Biol Med 49 2010 857 864
102. N. Vazzana, M.T. Guagnano, C. Cuccurullo, and et al. Endogenous secretory RAGE in obese women: association with platelet activation and oxidative stress J Clin Endocrinol Metab 97 2012 E1726 E1730
103. F. Santilli, N. Vazzana, P. Iodice, and et al. Effects of high-amount-high-intensity exercise on in vivo platelet activation: modulation by lipid peroxidation and AGE/RAGE axis Thromb Haemost 110 2013 1232 1240
104. A.J. Chien, and R.T. Moon WNTS and WNT receptors as therapeutic tools and targets in human disease processes Front Biosci 12 2011 448 457
105. T. Jin The WNT signalling pathway and diabetes mellitus Diabetologia 51 2008 1771 1780
106. S.F. Grant, G. Thorleifsson, I. Reynisdottir, and et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes Nat Genet 38 2006 320 323
107. K.I. Kim, K.U. Park, E.J. Chun, and et al. A novel biomarker of coronary atherosclerosis: serum DKK1 concentration correlates with coronary artery calcification and atherosclerotic plaques J Korean Med Sci 26 2011 1178 1184
108. P. Ferroni, S. Riondino, N. Vazzana, N. Santoro, F. Guadagni, and G. Davì Biomarkers of platelet activation in acute coronary syndromes Thromb Haemost 108 2012 1109 1123
109. S. Lattanzio, F. Santilli, R. Liani, and et al. Circulating dickkopf-1 in diabetes mellitus: association with platelet activation and effects of improved metabolic control and low-dose aspirin J Am Heart Assoc 18 2014 3
110. N. Voorzanger-Rousselot, D. Goehrig, T. Facon, P. Clézardin, and P. Garnero Platelet is a major contributor to circulating levels of Dickkopf-1: clinical implications in patients with multiple myeloma Br J Haematol 145 2009 264 266
111. N. Vazzana, P. Ranalli, C. Cuccurullo, and G. Davì Diabetes mellitus and thrombosis Thromb Res 129 2012 371 377
112. X. Li, J. Shan, W. Chang, and et al. Chemical and genetic evidence for the involvement of Wnt antagonist Dickkopf2 in regulation of glucose metabolism Proc Natl Acad Sci U S A 109 2012 11402 11407
113. P. Aukrust, F. Müller, T. Ueland, and et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes Circulation 100 1999 614 620
114. D.J. Angiolillo Antiplatelet therapy in type 2 diabetes mellitus Curr Opin Endocrinol Diabetes Obes 14 2007 124 131
115. C. Patrono, L.A. Garcia Rodriguez, R. Landolfi, and et al. Low-dose aspirin for the prevention of atherothrombosis N Engl J Med 353 2005 2373 2383
116. G. De Gaetano Collaborative Group of the Primary Prevention Project: low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice Lancet 357 2001 89 95
117. Steering Committee of the Physicians' Health Study Research Group: final report on the aspirin component of the ongoing Physicians' Health Study N Engl J Med 321 1989 129 135
118. H. Ogawa, M. Nakayama, T. Morimoto, and et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial JAMA 300 2008 2134 2141
119. J. Belch, A. MacCuish, I. Campbell, and et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease BMJ 337 2008 a1840
120. American Diabetes Association: cardiovascular disease and risk management Diabetes Care 38 2015 S49 S57
121. Antiplatelet Trialists' Collaboration: collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ 308 1994 81 106
122. M. Pignone Aspirin for primary prevention: a challenging decision J Am Heart Assoc 3 2014 pii:e001254
123. D.J. Angiolillo Variability in responsiveness to oral antiplatelet therapy Am J Cardiol 103 2009 27A 34A
124. F. Catella-Lawson, M.P. Reilly, S.C. Kapoor, and et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin N Engl J Med 345 2001 1809 1817
125. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, and et al. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention Am J Cardiol 97 2006 38 43
126. C. Watala, J. Pluta, J. Golanski, and et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin J Mol Med 83 2005 148 158
127. D. Capodanno, A. Patel, K. Dharmashankar, and et al. Pharmacodynamic effects of different aspirin dosing regimens in type2 diabetes mellitus patients with coronary artery disease Circ Cardiovasc Interv 4 2011 180 187
128. B. Rocca, F. Santilli, D. Pitocco, and et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes J Thromb Haemost 10 2012 1220 1230
129. F. Santilli, L. Mucci, and G. Davì TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus Intern Emerg Med 6 2011 203 212
130. G.N. Levine, E.R. Bates, J.C. Blankenship, and et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions J Am Coll Cardiol 58 2011 e44 e122
131. P.T. O'Gara, F.G. Kushner, D.D. Ascheim, and et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 2013 e78-140
132. J.L. Ferreiro, M. Ueno, S.D. Tomasello, and et al. Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study Circ Cardiovasc Interv 4 2011 273 279
133. L. Bonello, U.S. Tantry, R. Marcucci, and et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
134. M.J. Price, D.J. Angiolillo, P.S. Teirstein, and et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial Circulation 124 2011 1132 1137
135. G.W. Stone, B. Witzenbichler, G. Weisz, and et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study Lancet 382 2013 614 623
136. J.L. Ferreiro, and D.J. Angiolillo Diabetes and antiplatelet therapy in acute coronary syndrome Circulation 123 2011 798 813
137. G. Davì, A. Falco, and C. Patrono Lipid peroxidation in diabetes mellitus Antioxid Redox Signal 7 2005 256 268
138. 2+ mobilization by insulin via the inhibitory G-protein Gi J Biol Chem 279 2004 3254 3264
139. D.J. Angiolillo, E. Bernardo, M. Zanoni, and et al. Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease J Am Coll Cardiol 58 2011 30 39
140. D.J. Angiolillo, J.A. Jakubowski, J.L. Ferreiro, and et al. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease J Am Coll Cardiol 64 2014 1005 1014
141. D. Erlinge, C. Varenhorst, O.O. Braun, and et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo J Am Coll Cardiol 52 2008 1968 1977
142. M. Ueno, J.L. Ferreiro, S.D. Tomasello, and et al. Functional profile of the platelet P2Y12 signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease Thromb Haemost 105 2011 730 732
143. J. Van Giezen, L. Nilsson, P. Berntsson, and et al. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation J Thromb Haemost 7 2009 1556 1565
144. R.E. Wrishko, C.S. Ernest 2nd, D.S. Small, and et al. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38 J Clin Pharmacol 49 2009 984 998
145. S.D. Wiviott, E. Braunwald, D.J. Angiolillo, and et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38 Circulation 118 2008 1626 1636
146. S. James, D.J. Angiolillo, J.H. Cornel, and et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial Eur Heart J 31 2010 3006 3016
147. D. Alexopoulos, I. Xanthopoulou, E. Mavronasiou, and et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes Diabetes Care 36 2013 2211 2216
148. F. Santilli, D. Lapenna, S. La Barba, and G. Davì Oxidative-stress related mechanisms affecting response to aspirin in diabetes mellitus Free Radic Biol Med 80 December 2015 101 110
149. G. Davì, F. Santilli, and N. Vazzana Diabetes mellitus A.D. Michelson, Platelets 2013 E-Publishing Inc 711 732